NOXXON Pharma is a biotechnology company whose core focus is on cancer treatment. NOXXON is using its proprietary class of drugs called Spiegelmers* to target the tumor microenvironment, a new frontier in cancer treatment. NOXXON's goal is to significantly enhance the effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy.
NOXXON's Spiegelmer platform has generated a broad proprietary pipeline of clinical-stage assets including its lead cancer candidate NOX-A12 and additional candidates outside oncology: Pipeline
2017, January 06
Half-yearly report on the liquidity contract with INVEST securities
2017, January 04
NOXXON PHARMA licenses and assigns preclinical Spiegelmer programs to APTARION
2016, December 15
NOXXON Pharma signs clinical immuno-oncology collaboration agreement with MSD to study NOX-A12 combined with Keytruda (pembrolizumab) in pancreatic and colorectal cancer
• Spiegelbildliche Nukleinsäuren als pharmakologische Wirkstoffe.
• Spiegelmer Inhibition of MCP-1/CCR2 - Potential as an Adjunct Immunosuppressive Therapy in Transplantation.
• Intravitreal inhibition of complement C5a reduces choroidal neovascularization in mice.